Modeling HIV-1 mucosal transmission and prevention in humanized mice

Methods in Molecular Biology

Volumn 1354, Issue , 2016, Pages 203-220

  Veselinovic, Milena ^a   Charlins, Paige ^a   Akkina, Ramesh ^a  

^a NONE

Author keywords

HIV infection in humanized mice; HIV mucosal transmission; HIV pre exposure prophylaxis; HIV vaginal and rectal transmission; HIV 1 animal models; HIV 1 PrEP; Hu HSC and BLT mice; Modeling HIV transmission and prevention; PK PD in HIV 1 PrEP; Preparation of humanized mice

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INFECTION PREVENTION; METHODOLOGY; MOUSE; MUCOSA; NEWBORN; NONHUMAN; SEXUAL TRANSMISSION; VIREMIA; VIRUS TRANSMISSION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL SEPARATION; DISEASE MODEL; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; LIVER TRANSPLANTATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCID MOUSE; THYMUS; TRANSMISSION; TRANSPLANTATION; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; LIVER TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, SCID; MUCOUS MEMBRANE; THYMUS GLAND;

EID: 84952815156     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3046-3_14     Document Type: Chapter

References (27)

1. Akkina R (2013) New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435:14–28. doi: 10.1016/j.virol.2012.10.007
2. Brehm MA, Wiles MV, Greiner DL, Shultz LD (2014) Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods 410C:3–17. doi: 10.1016/j.jim.2014.02.011
3. Denton PW, Garcia JV (2011) Humanized mouse models of HIV infection. AIDS Rev 13(3):135–148
4. Garcia S, Freitas AA (2012) Humanized mice: current states and perspectives. Immunol Lett 146:1–7. doi: 10.1016/j.imlet.2012.03.009
5. Maartens G, Celum C, Lewin SR (2014) HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384:258–271. doi: 10.1016/S0140-6736(14)60164-1
6. Romano J, Kashuba A, Becker S, Cummins J, Turpin J, Veronese F, Antiretroviral Pharmacology In HIVPTTP (2013) Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses 29:1418–1427. doi: 10.1089/AID.2013.0122
7. Baeten JM, Celum C (2013) Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med 368:83–84
8. Hankins CA, Dybul MR (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 8:50–58. doi: 10.1097/COH.0b013e32835b809d
9. Veazey RS (2013) Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS 8:295–303. doi: 10.1097/COH.0b013e328361d096
10. Trezza CR, Kashuba AD (2014) Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet 53:611–624. doi: 10.1007/s40262-014-0148-z
11. Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba AD, Akkina R (2014) HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology 464–465:253–263. doi: 10.1016/j.virol.2014.07.008
12. Akkina RK, Rosenblatt JD, Campbell AG, Chen IS, Zack JA (1994) Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 84:1393–1398
13. Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R (2008) Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/-gammac-/-(RAG-hu) mice. Virology 373:342–351. doi: 10.1016/j.virol.2007.11.020
14. Berges BK, Akkina SR, Remling L, Akkina R (2010) Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397:100–103. doi: 10.1016/j.virol.2009.10.034
15. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R (2006) HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology 3:76. doi: 10.1186/1742-4690-3-76
16. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG (2006) Reconstitution of a functional human immune system in immunodefi cient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108:487–492. doi: 10.1182/blood-2005-11-4388
17. Bristol GC, Gao LY, Zack JA (1997) Preparation and maintenance of SCID-hu mice for HIV research. Methods 12:343–347
18. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV (2008) Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5:e16. doi: 10.1371/journal.pmed.0050016
19. Denton PW, Garcia JV (2012) Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 20:268–274. doi: 10.1016/j.tim.2012.03.007
20. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati P, Dabis F, Rouzioux C (2005) Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodefi ciency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43:2709–2717. doi: 10.1128/JCM.43.6.2709-2717.2005
21. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R (2010) Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 5:e15257. doi: 10.1371/journal.pone.0015257
22. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R (2011) A topical microbicide gel formulationof CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 6:e20209. doi: 10.1371/journal.pone.0020209
23. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV (2011) One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 85:7582–7593. doi: 10.1128/JVI.00537-11
24. Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV (2013) Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One 8:e60024. doi: 10.1371/journal.pone.0060024
25. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872. doi: 10.1371/journal.ppat.1003872
26. Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, Su L, Swanstrom R, Kashuba AD, Margolis DM (2009) Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/-mouse. J Virol 83:8254–8258. doi: 10.1128/JVI.00580-09
27. Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, Moreno ME, Rivera JM, Ronquillo RE, Sloan B, Black PL (2007) Validation of the SCID-hu Thy/Livmouse model with four classes of licensed antiretrovirals. PLoS One 2:e655. doi: 10.1371/journal.pone.0000655